Portal de Periódicos da CAPES

Long-Term Single Center Experience in Treating Plaque Psoriasis With Guselkumab

2020; SAGE Publishing; Volume: 24; Issue: 6 Linguagem: Inglês

10.1177/1203475420932514

1615-7109

Khalad Maliyar, Ashley O’Toole, Melinda Gooderham,

Asthma and respiratory diseases

Clinical trial data have shown guselkumab, an interleukin-23 inhibitor, to be efficacious and safe for the treatment of psoriasis. However, there is very little real-world experience using guselkumab in the community setting that has been documented.The goal of this study was to determine real-life outcomes of guselkumab use in patients with moderate-to-severe psoriasis in a community dermatology practice.A retrospective chart review of electronic medical records was conducted in patients with moderate-to-severe psoriasis who were prescribed guselkumab at a community dermatology office in Ontario, Canada.Of the 89 patients who received at least 1 dose of guselkumab, 79 had follow-up information at the time of review, with 71 patients receiving ongoing treatment. In our cohort of patients, 73.3% achieved clinically significant clearance of psoriasis with a global assessment of clear or almost clear defined as a body surface area involvement of <1%. Guselkumab was generally well tolerated and caused no serious adverse events. The most common reported side effects were nasopharyngitis, headaches, upper respiratory tract infections, gastrointestinal upset, and arthralgia.Overall, guselkumab was a safe and well-tolerated treatment with significant clinical improvement in our patient population.